Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Zinc showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · people with AMD
1 finding from 1 review
no estimate extracted
286 participants
Very low
Resource use and costs · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with HIV infection
It is very uncertain whether zinc changes mortality compared with placebo (very low certainty).
1 finding from 1 review
Rate of diarrhoea · adults with HIV infection
It is very uncertain whether zinc changes rate of diarrhoea compared with placebo (very low certainty).
1 finding from 1 review
Change in CD4 count · adults with HIV infection
1 finding from 1 review
Change in viral load · adults with HIV infection
1 finding from 1 review
All‐cause mortality · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in all‐cause mortality compared with no zinc supplementation (high certainty).
1 finding from 1 review
Mortality due to all‐cause diarrhea · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to all‐cause diarrhea compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Mortality due to LRTI · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to LRTI compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Mortality due to malaria · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to malaria compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Diarrhea · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation probably leads to lower incidence of all‐cause diarrhea compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Incidence of LRTI · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in incidence of LRTI compared with no zinc supplementation (high certainty).
1 finding from 1 review
Height (cm) · otherwise healthy children aged 6 months to 12 years of age
1 finding from 1 review
Participants with ≥ 1 vomiting episode · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation leads to higher participants with ≥ 1 vomiting episode compared with no zinc supplementation (high certainty).
1 finding from 1 review
All‐cause mortality (between start of intervention and end of · preterm infants
Enteral zinc supplementation may leads to lower all‐cause mortality (between start of intervention and end of compared with no zinc supplementation (low certainty).
1 finding from 1 review
Neurodevelopmental disability at 18 to 24 months among survivors · preterm infants
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Bronchopulmonary dysplasia · preterm infants
Enteral zinc supplementation showed no clear difference in bronchopulmonary dysplasia compared with no zinc supplementation (low certainty).
1 finding from 1 review
Retinopathy of prematurity · preterm infants
Enteral zinc supplementation showed no clear difference in retinopathy of prematurity compared with no zinc supplementation (low certainty).
1 finding from 1 review